---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: NATIVE"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: NATIVE. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 112 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence/native"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: NATIVE

<a id="heading-3.1.2"></a>

## 3.1.2 NATIVE

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov record

> “The purpose of this research is to evaluate the efficacy and the safety of two doses of IVA337 (800mg, 1200 mg) per day for 24 weeks versus placebo in adult NASH patients with liver steatosis and moderate to severe necroinflammation without cirrhosis.”
> “A Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-range, Proof-of-concept, 24-week Treatment Study of IVA337 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.1-2"></a>

#### Study objective in the protocol

> “The study objective is to assess the safety and the efficacy on the activity part of the SAF histological score (inflammation and ballooning) of a 24-week treatment with two doses of lanifibranor (800, 1200 mg/24h) in NASH adult patients.”
> “The goal of the proposed study is to show improvement of cardinal NASH histopathologic features as well as safety data after a 6-month treatment.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.1-3"></a>

#### Objective stated in the design paper

> “NATIVE study (EudraCT: 2016-001979-70, NCT: NCT03008070) aims to assess the safety and the efficacy of a 24-week treatment with lanifibranor (800 and 1200 mg/day) in adult non-cirrhotic NASH patients.”

Source: [Francque et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33038502/)

<a id="topic-3.1.2.1-4"></a>

#### Aim of the trial in the published report

> “Here, we report the results of the NASH Trial to Validate IVA337 Efficacy (NATIVE), a phase 2b, double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of lanifibranor in patients with biopsy-proven, noncirrhotic NASH with severe disease activity.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Study dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2017-02-07”
> “Primary Completion (Actual) 2020-02-20”
> “Study Completion (Actual) 2020-03-16”
> “Results First Posted 2021-04-12”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.2-2"></a>

#### Registered locations

> “This study has 85 locations”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.2-3"></a>

#### Countries and screening period in the published report

> “NATIVE was approved by independent ethics committees and the appropriate authorities in 16 countries where at least one patient underwent randomization (Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).”
> “From February 2017 through July 2019, a total of 868 patients underwent screening, and 247 patients were randomly assigned in a 1:1:1 ratio to receive 1200 mg of lanifibranor (83 patients), 800 mg of lanifibranor (83 patients), or placebo (81 patients) orally once daily for 6 months (Fig. S3).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.2-4"></a>

#### Recruitment period in the registry results

> “Recruitment of patients started in February 2017, and last patient was recruited on March 2019. A total of 868 patients were screened for the study.”

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="topic-3.1.2.2-5"></a>

#### Planned sites and study period in the protocol

> “The study will be performed in at least 60 sites across Europe, United States of America (USA) and other countries worldwide (incl. Canada, Australia and Republic of Mauritius).”
> “Studied period: First enrolment: Q1 2017. Expected completion date: 2020.”
> “The total duration of the study is up to 38 months, i.e. at least 30 months of enrollment period and up to 8 months of patient participation.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.2-6"></a>

#### Sponsor and other study identifiers

> “Sponsor Inventiva Pharma”
> “IVA_01_337_HNAS_16_002”
> “2016-001979-70 ( EudraCT Number )”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Phase 2b, randomized, double-blind, placebo-controlled design

> “In this phase 2b, double-blind, randomized, placebo-controlled trial, patients with noncirrhotic, highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo once daily for 24 weeks.”
> “Patients were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of oral lanifibranor or placebo once daily for 24 weeks; randomization was stratified according to diabetic status (absence or presence).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.3-2"></a>

#### Design summary in the design paper

> “NATIVE is a Phase 2b randomised, placebo-controlled, double-blind, parallel-assignment, dose-range study.”
> “This study will evaluate the efficacy of a 24-week treatment of NASH with lanifibranor based on histological evaluations (SAF score) by biopsy.”

Source: [Francque et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33038502/)

<a id="topic-3.1.2.3-3"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Study type | “Interventional” |
| Phase | “Phase 2” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Enrollment | “Enrollment (Actual) 247” |

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.3-4"></a>

#### Treatment groups, blinding, and study duration in the ClinicalTrials.gov record

> “Randomized (stratified on diabetes), placebo-controlled, double-blind, parallel-assignment, dose-range multicenter study”
> “There are 3 parallel treatment groups: placebo, IVA337 800mg once a day (Quaque Die, QD) and IVA337 1200mg QD (identical tablets of 400mg IVA337 or placebo). Both, patient and investigator are blinded.”
> “For each patient, the study duration will be an overall of 6 to 8 months (with a 10-day to 4-week selection period, a 24-week treatment period and a 4-week follow-up period).”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.3-5"></a>

#### Study arms, visit schedule, and selection period in the protocol

> “The study is a three arm (placebo, lanifibranor 800 and 1200 mg/day), randomized (1:1:1), double-blind, placebo-controlled, multicenter, 24-week treatment study.”
> “Patients will undergo 6 visits: screening visit (V-1, -8 weeks to -2 weeks), randomization (V0), interim visit 1 (V1, 4 weeks after V0), interim visit 2 (V2, 10 weeks after V1), End of treatment visit (V3, 10 weeks after V2) and a follow-up visit (4 weeks after V3).”
> “For each patient, the study duration will be an overall of 6 to 8 months (with a 3-day to 4-week selection period, a 24-week treatment period and a 4-week follow-up period).”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.3-6"></a>

#### Randomization procedure in the protocol

> “Patients will be randomized equally 1:1:1 to either dose of lanifibranor or placebo stratified on presence/absence of diabetes.”
> “The randomization list will be setup with blocs of size equal to 6.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.3-7"></a>

#### Screening biopsy and centralized histology reading in the protocol

> “As the main efficacy goal of the study is to assess treatment effect on histologic features of NASH, there will be a centralized reading of slides of a liver biopsy to confirm the diagnosis and assess the severity at screeing phase (V-1) and end of treatment visit (V3).”
> “Patients will be withdrawn from the study at this step in case of TE > 12.5 kPa (i.e. high probability of cirrhosis).”
> “After validation of the histological criteria by the central reading assessment, patients can be randomized.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.3-8"></a>

#### Rationale for the placebo comparator and the 6-month duration in the protocol

> “Placebo is chosen as the comparator, as there is no licensed treatment for NASH.”
> “Therefore, taking into account the postulated end points, a treatment of 6 months in a proof of concept study is sufficient to assess study drug efficacy and will furthermore also limit the time on placebo for one third of the study patients.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.3-9"></a>

#### Trial oversight and sponsor role

> “The sponsor (Inventiva Pharma) designed the trial and monitored the trial sites, collected the data, and analyzed the data.”
> “An earlier version of the manuscript was drafted with the assistance of a medical writer (funded by the sponsor) under the guidance of the authors.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.3-10"></a>

#### Management after the end of treatment in the protocol

> “The trial treatment is stopped after V3.”
> “Safety of withdrawal from treatment groups is assessed during a 30-day assessment phase.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Key eligibility criteria in the published report

> “Patients were eligible for inclusion if they were 18 years of age or older and had noncirrhotic NASH (the diagnosis of which required a Steatosis, Activity, Fibrosis [SAF] grade of 1 or higher for steatosis [range, 0 to 3], hepatocellular ballooning [range, 0 to 2], and lobular inflammation [range, 0 to 2] on liver biopsy); higher grades indicate more-severe disease activity.”
> “The diagnosis was confirmed by a centrally read biopsy sample obtained at screening or in the preceding 6 months (patients whose diagnosis was not confirmed at screening had to have a stable body weight, defined as no more than a 5% loss of initial body weight between the time of biopsy and screening).”
> “Patients with stage F4 fibrosis, classified according to the criteria of both the SAF and NASH Clinical Research Network (NASH CRN) (stages range from F0 [no fibrosis] to F4 [cirrhosis]),10,11 were excluded.”
> “A score of 3 or higher on the SAF-A (the activity part of the SAF scoring system that incorporates the scores for hepatocellular ballooning and lobular inflammation) was also a criterion for eligibility.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.4-2"></a>

#### No fibrosis-stage inclusion criterion other than the exclusion of cirrhosis

> “Eligible adult patients with a confirmed histological diagnosis of NASH should have a SAF Activity score of 3 or 4 (>2) and a SAF Steatosis score ≥ 1. There is no specific criterion related to the fibrosis score except that patients with cirrhosis (F4) were excluded.”

Source: [Francque et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33038502/)

<a id="topic-3.1.2.4-3"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

> “NASH histological diagnosis according to the currently accepted definition of both EASL and AASLD, requiring the combined presence of steatosis (any degree ≥ 5%) + lobular inflammation of any degree + liver cell ballooning of any amount, on a liver biopsy performed ≤ 6 months before screening in the study or at screening and confirmed by central reading during the screening period and”
> “SAF Activity score of 3 or 4 (>2)”
> “SAF Steatosis score ≥ 1”
> “SAF Fibrosis score < 4”
> “Subject agrees to have a liver biopsy performed after 24 weeks of treatment.”
> “If applicable, have a stable type 2 diabetes, defined as HbA1c ≤ 8.5% and fasting glycemia <10 mmol/L, no changes in medication in the previous 6 months, and no new symptoms associated with decompensated diabetes in the previous 3 months.”
> “Have a stable weight since the liver biopsy was performed defined by no more than a 5 % loss of initial body weight.”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.4-4"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

> “History of sustained excess alcohol ingestion: daily alcohol consumption > 30 g/day (3 drinks per day) for males and > 20 g/day (2 drinks per day) for females.”
> “Unstable metabolic condition: Weight change > 5kg in the last three months, diabetes with poor glycemic control (HbA1c > 8.5%), introduction of an antidiabetic or of an anti-obesity drug/malabsorptive or restrictive bariatric (weight loss) surgery in the past 6 months prior to screening.”
> “Significant systemic or major illnesses other than liver disease, including congestive heart failure (class C and D of the American Heart Association , AHA), unstable coronary artery disease, cerebrovascular disease, pulmonary disease, renal failure, organ transplantation, serious psychiatric disease, malignancy that, in the opinion of the investigator, would preclude treatment with IVA337 and/or adequate follow up.”
> “Body mass index (BMI) >45 kg/m2.”
> “Type 1 diabetes and type 2 diabetic patient on insulin.”
> “Fasting Triglycerides > 300 mg/dL.”
> “History of, or current cardiac dysrhythmias and/or a history of cardiovascular disease event, including myocardial infarction, except patients with only well controlled hypertension. Any clinically significant ECG abnormality reported by central ECG reading.”
> “Osteopenia or any other well documented Bone disease. Patient without well documented osteopenia treated with vitamin D and/or Calcium based supplements for preventive reasons can be included.”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.4-5"></a>

#### Laboratory criteria for compensated liver disease in the protocol

> “Compensated liver disease with the following hematologic and biochemical criteria before randomization:”
> “ALT < 10xULN”
> “Hemoglobin ≥ 110 g/L (11g/dL) for females and ≥ 120 g/L (12g/dL) for males”
> “Platelets > 100 10^9/L (100 10^3/µL)”
> “Albumin > 36 g/L (3.6 g/dL)”
> “International Normalized Ratio (INR) < 1.4”
> “Serum creatinin < 115 µmol/L (1.3 mg/dL) (men) or < 97 µmol/L (1.1 mg/dL) (women) or estimated glomerular filtration rate ≥ 60 mL/min/1.73m2”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.4-6"></a>

#### Prohibited concomitant medications in the protocol

> “If not specified, the following treatment must be stopped at the latest before randomization.”
> “PPAR Gamma agonists, PPAR Alpha agonists (fibrates), ezetimibe,”
> “Glucagon like peptide-1 receptor agonists (incl. liraglutide, exenatide),”
> “Vitamins E (alpha-tocopherol),”
> “Anticoagulants (incl. warfarin, dabigatran, rivaroxaban, apixaban),”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.4-7"></a>

#### Permitted antidiabetic and lipid-lowering medications in the protocol

> “Treatments are allowed within certain restrictions (described above and below) and provided that they have been kept at stable doses for at least 6 months before the pre-treatment biopsy.”
> “Dipeptidyl peptidase-4 inhibitors,”
> “Sodium-glucose transport protein 2 inhibitors: canagliflozin, dapagliflozin and empagliflozin.”
> “Hyperlipidemia: only statins at stable doses within the past 3 months before pre-study treatment biopsy will be allowed.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Doses, schedule, and duration in the published report

> “Patients were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of oral lanifibranor or placebo once daily for 24 weeks; randomization was stratified according to diabetic status (absence or presence).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.5-2"></a>

#### Arms in the ClinicalTrials.gov record

| Arm | Description |
| --- | --- |
| Experimental: IVA337 1200mg | “IVA337 400mg, once a day (Quaque Die, QD) with food” |
| Experimental: IVA337 800mg | “IVA337 400mg, once a day (Quaque Die, QD) with food” |
| Placebo Comparator: Placebo | “Placebo to match, once a day (Quaque Die, QD) with food” |

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.5-3"></a>

#### Tablets, kits, and administration with breakfast in the protocol

> “Tablets of lanifibranor 400 mg, two doses of lanifibranor (800 and 1200 mg QD), i.e. 3 tablets of 400 mg/placebo per os, during breakfast, once daily (QD) will be evaluated.”
> “Each active tablet contains 400 mg of the active substance lanifibranor in an immediate release formulation.”
> “Placebo Kit: Morning (P+P+P)”
> “800 mg Kit: Morning (P+A+A)”
> “1200 mg Kit: Morning (A+A+A)”
> “Where P denotes the placebo tablet and A denotes the active tablet (400 mg).”
> “They are instructed to take morning 3 tablets with food, i.e. one tablet from each of the containers A, B, and C. The overall treatment duration is 24 weeks.”
> “Dosage modifications are not permitted.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.5-4"></a>

#### Dose selection and food intake rationale in the protocol

> “To improve bioavailability, drug intake is combined with food.”
> “Doses have been selected based on the available biomarker (adiponectin, HDL cholesterol, triglycerides) results in diabetes type 2 patients (Phase IIa study):”
> “The two doses chosen for the trial demonstrated significant improvement in biomarkers of PPAR α, γ and probably δ in diabetic patients.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.5-5"></a>

#### Treatment compliance measures in the protocol

> “remaining tablets will be counted /recorded in the eCRF by sites and monitored by the Clinical Research Associate”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using SAF Activity Score Decrease of at Least 2 Points Without Worsening of Fibrosis as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Primary end point definition in the published report

> “The primary end point was a decrease of at least 2 points from baseline to week 24 in the SAF-A score and no worsening of fibrosis (i.e., no increase in fibrosis stage based on SAF–NASH CRN criteria).”
> “SAF-A scores range from 0 to 4, with higher scores indicating more-severe disease activity.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.6.1-2"></a>

##### Primary outcome measure in the ClinicalTrials.gov record

> “SAF Activity Score (SAF-A) Decrease of at Least 2 Points With no Worsening of the CRN Fibrosis Score (CRN-F)”
> “SAF-A is the activity part of the Steatosis Activity Fibrosis [SAF] histological score, calculated as the sum of lobular inflamation score and balloning score.”
> “No worsening of fibrosis means that the CRN fibrosis score (CRN-F) remains stable or decreases.”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.6.1-3"></a>

##### Primary endpoint and responder definition in the protocol

> “Responder is defined as a decrease from baseline to week 24 of at least 2 points of the SAF activity score combining hepatocellular inflammatory and ballooning without worsening of fibrosis. Any stage increase of fibrosis is considered fibrosis progression.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.6.1-4"></a>

##### Primary endpoint in the design paper

> “The primary efficacy endpoint is a 2-point reduction in the activity part of the Steatosis Activity Fibrosis (SAF) histological score (combining inflammation and ballooning) without worsening of fibrosis.”

Source: [Francque et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33038502/)

<a id="topic-3.1.2.6.1-5"></a>

##### Rationale for scoring activity separately from steatosis in the published report

> “Steatosis was assessed separately because it does not reflect liver-cell damage and inflammation per se, outcomes that are included in the SAF concept of “activity” (Fig. S1).”
> “While disease activity should reflect ongoing damage and inflammation, the inclusion of steatosis as part of a composite activity score introduces a risk that these outcomes may be overestimated.”
> “We therefore used the SAF scoring system, which assesses steatosis separately from activity and accounts for necroinflammation without steatosis, in the selection of patients for the trial and to define the primary end point.”
> “The use of the SAF-A score enriched the trial with patients more likely to benefit from pharmacologic treatment. As for the other histologic end points, the validity of the use of the SAF-A score to define the primary end point as a surrogate for long-term outcomes warrants further study.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.6.1-6"></a>

##### Justification for the SAF activity score in the protocol

> “While steatosis is considered to be a relatively benign lesion, ballooning and inflammation define the so-called “activity” of NASH. Activity is very likely driving fibrogenesis, which is the main histological long term prognostic factor for liver-related and also non-liver-related mortality associated with NASH. Reducing activity to prevent fibrogenesis is the treatment goal evaluated in this clinical trial.”
> “The activity sub score of the SAF score has been chosen as the main assessment criteria (63).”
> “By giving an equal weight to both lesion and not including steatosis into this score, a grade of activity > 2 ensures to get at least 95% of NASH (63).”
> “Since this score includes steatosis, which is supposed to be a benign lesion, and underweight ballooning (graded from 0 to 2) compared to steatosis and inflammation (each being graded from 0 to 3), this score does not reflect activity of the disease as accurately as does the activity score of SAF.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.6.1-7"></a>

##### Liver histology as the efficacy measure in FDA and EMA approved phase 3 trials, as stated in the protocol

> “As there is still no non-invasive tool sufficiently validated to accurately assess both the diagnosis as well as the treatment response in NASH, the only reliable tool to assess treatment efficacy is liver histology.”
> “Also in the current Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved Phase III trials, treatment efficacy is defined based on histological criteria and consequently liver biopsy is a prerequisite to accurately evaluate both the baseline liver status of the patient as well as the efficacy of the treatment after a predefined treatment period.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.6.1-8"></a>

##### Regulatory context for histologic surrogate end points in the published report

> “Resolution of NASH and regression of fibrosis are currently considered to be likely surrogate outcomes for the prevention of progression to cirrhosis and associated complications.”
> “When the analysis was restricted to patients with significant (stage F2) or advanced (stage F3) fibrosis (i.e., those who compose the target population for the treatment of noncirrhotic NASH according to regulatory guidance), similar results were obtained, a finding that supports the potential for benefits with lanifibranor as compared with placebo.”
> “Regression of fibrosis in NASH is associated with decreased risk of liver-related events19 and is a surrogate end point for regulatory approval.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.6.1-9"></a>

##### Secondary histologic and nonhistologic end points in the published report

> “Secondary histologic end points included resolution of NASH (defined as a ballooning grade of 0 and a lobular inflammation grade of ≤1) and no worsening of fibrosis; improvement in fibrosis stage of at least 1 and no worsening of NASH (i.e., no worsening in either steatosis, ballooning, or lobular inflammation); Nonalcoholic Fatty Liver Disease Activity Score (NAS) improvement (defined as a decrease of ≥2 points from baseline to week 24 in the NAS, which is the sum of the scores for steatosis [range, 0 to 3], ballooning [range, 0 to 2], and lobular inflammation [range, 0 to 3], with higher scores indicating greater disease activity) and no worsening of fibrosis12; resolution of NASH and an improvement in fibrosis stage of at least 1 (a composite end point); change in scores for the components of the SAF and NASH CRN scoring system (steatosis, activity, inflammation, ballooning, and fibrosis); and change in the modified Ishak score.”
> “Nonhistologic secondary end points included changes in liver enzyme levels (alanine aminotransferase, aspartate aminotransferase, and γ-glutamyltransferase); changes in measures of glucose metabolism (fasting levels of glucose, insulin, and glycated hemoglobin and homeostatic model assessment of insulin resistance [HOMA-IR] index score); changes in lipid levels (total cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL] cholesterol, triglycerides, and apolipoprotein A1); change in adiponectin level; and changes in inflammatory markers (fibrinogen, high-sensitivity C-reactive protein, α2-macroglobulin, and haptoglobin).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.6.1-10"></a>

##### Exploratory end points, including quality of life, in the published report

> “Exploratory end points included change in the apoptosis marker cytokeratin 18 M30; changes in serum markers of fibrosis and collagen turnover (ratio of tissue inhibitor of metalloproteinase 1 to matrix metalloproteinase 2, N-terminal type III collagen propeptide [Pro-C3] level, and scores on the Enhanced Liver Fibrosis test and Fibrosis-4 index); changes in other lipid levels (apolipoprotein B and C3); changes on transient elastography (FibroScan, Echosens) with controlled attenuation parameter; and change in quality of life.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.6.1-11"></a>

##### Quality-of-life questionnaires assessed in the protocol

> “QOL questionnaires including the Flinders Fatigue scale (FFS) and the SF-36v2 health survey”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.6.1-12"></a>

##### Registered secondary end point definitions for NASH resolution and fibrosis improvement

> “Resolution of NASH is defined as a CRN Inflammation score equal to 0 or 1, and a CRN Ballooning score equal to 0. No worsening of fibrosis means that the CRN fibrosis score remains stable or decreases.”
> “Improvement of fibrosis is defined as a decrease of at least one stage in CRN Fibrosis score. No worsening of NASH is defined as no increase of CRN Steatosis score, no increase of CRN Inflammation score ans no increase of CRN Ballooning score.”
> “NASH improvement is defined as a decrease of at least 2 points in NAS score (sum of CRN Steatosis, Inflammation and Ballooning scores) without worsening of CRN Fibrosis score.”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.6.1-13"></a>

##### Histology reading by one blinded pathologist

> “All biopsy samples were read serially by one pathologist who was unaware of the time at which the samples were obtained (baseline or end of assigned regimen), the trial-group assignment, and the identity of the person who assessed the adequacy of the samples.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.6.1-14"></a>

##### Protocol version 5.0, July 2019: secondary endpoints updated

> “Version 5.0 July 09th, 2019 Updating the secondary endpoints, safety and biomarkers analysis performed”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Planned sample size and power in the protocol

> “At least 300 patients will be screened, to randomize 225 patients (75 patients/arm).”
> “The expected rate of responders according to the retained definition was estimated to 10% for the placebo by a group of clinical expert. An excess rate of responders of 20% was accepted as clinically pertinent.”
> “The sample size required to reach a power of at least 80% is 72 patients per group with a two-sided alpha of 0.025 (adjustment for multiplicity).”
> “The sample size is therefore rounded in the conservative side of 75 patients per group.”
> “In case the end of study liver biopsy slides are not available or not interpretable in more than 5% of patients, an amendment will be submitted to increase sample size accordingly.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.7.1-2"></a>

##### Randomized participants and per-protocol population in the published report

> “From February 2017 through July 2019, a total of 868 patients underwent screening, and 247 patients were randomly assigned in a 1:1:1 ratio to receive 1200 mg of lanifibranor (83 patients), 800 mg of lanifibranor (83 patients), or placebo (81 patients) orally once daily for 6 months (Fig. S3).”
> “All patients who had undergone randomization received at least one dose of the assigned regimen, and no patient was excluded from the full analysis population.”
> “Major protocol deviations occurred in 53 patients (34 did not have biopsy data available at the end of the treatment period and 19 had other major protocol deviations), who were not included in the per-protocol population, which comprised 194 patients (Table S3).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.7.1-3"></a>

##### Missing week 24 biopsies by group in the full analysis population

> “Missing data for the 34 patients in the full analysis population (11 in the 800-mg lanifibranor group, 9 in the 1200-mg lanifibranor group, and 14 in the placebo group had missing biopsy samples at week 24) were handled with multiple imputation (details are provided in the Supplementary Appendix).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.7.1-4"></a>

##### Enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 247”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.7.1-5"></a>

##### Participants analyzed at baseline in the registry results

> “Overall Number of Baseline Participants 83 83 81 247”

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Full analysis, safety, and per-protocol populations in the published report

> “The full analysis population included all patients who underwent randomization and received at least one dose of the assigned regimen and was identical to the safety analysis population.”
> “The per-protocol population included all patients who had biopsy data available at the end of the treatment period and no major protocol deviations.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.7.2-2"></a>

##### Analysis sets defined in the protocol

> “The full analysis set consists of all randomized patients who received at least one dose of the assigned treatment.”
> “The randomized set of patients consists of all randomized patients.”
> “This set is composed of all patients free from major protocol deviation which can bias the estimate of the treatment effect.”
> “The safety set of patients consists of the FAS who will have taken at least one dose of treatment and who have at least one post-baseline assessment of safety, regardless any protocol deviations.”
> “The primary population will be the intent to treat FAS population composed of all randomized subject who received at least one dose.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.7.2-3"></a>

##### Primary analysis method and missing-data rule in the protocol

> “The primary tests of hypotheses will be the Cochran Mantel Haenszel test stratified on diabetes comparing the high dose to placebo and the low dose to placebo.”
> “The primary rule for handling the missing data is to consider non-responders all patients who are not confirmed responders.”
> “There is no planned interim analysis for success.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.7.2-4"></a>

##### Multiplicity adjustment, multiple imputation, and sensitivity analyses in the published report

> “For statistical tests, the type I error risk was set at 5% (two-sided) in accordance with the protocol. Adjustments for multiplicity testing in the primary analysis were performed with the use of the Hochberg procedure; each active-treatment group was compared with the placebo group. No multiplicity adjustments for the secondary and exploratory end points were defined.”
> “Comparisons of histologic responses among the trial groups were performed with the use of the Cochran–Mantel–Haenszel test stratified according to diabetic status at baseline.”
> “The primary analyses that we report here were performed in the full analysis population with the use of multiple imputation for missing data, including missing or inadequate biopsy data at the end of the treatment period (see the Supplementary Appendix). We also report the analyses that were performed with the use of single imputation to treat missing data as nonresponses, as specified in the statistical analysis plan.”
> “In addition, sensitivity analyses were conducted on the basis of complete cases (i.e., those with biopsy samples available at both baseline and the end of assigned regimen), as specified in the statistical analysis plan. Other analyses were performed in the per-protocol population and in the subgroups defined according to significant (moderate) or advanced fibrosis and diabetic status.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.7.2-5"></a>

##### Analysis of continuous secondary end points in the published report

> “Comparisons of quantitative secondary end points among the trial groups were assessed with the use of mixed models for repeated measures, with the absolute change in the value of the continuous variable from baseline as the end point; the time, trial group, diabetic status, trial-group–by–time interaction, and baseline value of the variable as fixed effects; a time-repeated effect within each subject; and an unstructured variance–covariance matrix.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Screening, randomization, and completion in the published report

> “From February 2017 through July 2019, a total of 868 patients underwent screening, and 247 patients were randomly assigned in a 1:1:1 ratio to receive 1200 mg of lanifibranor (83 patients), 800 mg of lanifibranor (83 patients), or placebo (81 patients) orally once daily for 6 months (Fig. S3).”
> “Among the 247 patients in the full analysis population, 228 completed the trial (77 patients in each lanifibranor group and 74 in the placebo group).”
> “Major protocol deviations occurred in 53 patients (34 did not have biopsy data available at the end of the treatment period and 19 had other major protocol deviations), who were not included in the per-protocol population, which comprised 194 patients (Table S3).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.1-2"></a>

##### Screen failures in the registry results

> “A total of 247 patients were randomised, and 621 were not randomised.Main reason for non randomization was inclusion/exclusion criteria not met (470 - 76%).”

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="topic-3.1.2.8.1-3"></a>

##### Participant flow and reasons for not completing in the registry results

| Milestone or reason | Lanifibranor 1200mg | Lanifibranor 800mg | Placebo |
| --- | --- | --- | --- |
| Started | “83” | “83” | “81” |
| Completed | “77” | “77” | “74” |
| Not completed | “6” | “6” | “7” |
| Adverse event | “3” | “3” | “3” |
| Lost to follow-up | “1” | “1” | “0” |
| Non compliance | “0” | “1” | “1” |
| Use of prohibited drug | “0” | “0” | “2” |
| Withdrawal by patient and adverse event non fatal | “0” | “1” | “0” |
| Withdrawal by subject | “2” | “0” | “1” |

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Baseline characteristics summarized in the published report

> “The mean age of the patients was 54 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 33; 144 (58%) were female, 232 (94%) were White, and 103 (42%) had type 2 diabetes mellitus.”
> “Significant or advanced fibrosis (stages F2 and F3, respectively) was present in 188 patients (76%), and most patients had highly active NASH (the mean [±SD] SAF-A score was 3.3±0.5, and 73% had an NAS of ≥6, which indicates high disease activity). The median duration between screening biopsy and randomization was 2.3 months (range, 0.5 to 9.2).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.2-2"></a>

##### Demographic and clinical characteristics at baseline, full analysis population

| Characteristic | Lanifibranor 1200 mg (N=83) | Lanifibranor 800 mg (N=83) | Placebo (N=81) | Overall (N=247) |
| --- | --- | --- | --- | --- |
| Female sex, no. (%) | “49 (59)” | “54 (65)” | “41 (51)” | “144 (58)” |
| Age, yr | “52.2±13.8” | “55.0±10.4” | “53.4±13.1” | “53.6±12.5” |
| White race, no. (%) | “78 (94)” | “80 (96)” | “74 (91)” | “232 (94)” |
| Weight, kg | “93.0±19.9” | “91.6±19.3” | “95.1±17.3” | “93.2±18.9” |
| Body-mass index | “33.3±5.5” | “32.5±5.5” | “32.8±5.1” | “32.9±5.4” |
| Type 2 diabetes mellitus, no. (%) | “35 (42)” | “33 (40)” | “35 (43)” | “103 (42)” |
| Median time between screening biopsy and randomization (range), mo | “2.4 (0.5–7.0)” | “2.6 (0.5–9.2)” | “2.0 (0.5–7.4)” | “2.3 (0.5–9.2)” |
| Steatosis grade | “2.6±0.6” | “2.6±0.7” | “2.5±0.7” | “2.5±0.7” |
| Lobular inflammation grade | “1.5±0.5” | “1.5±0.5” | “1.5±0.5” | “1.5±0.5” |
| Ballooning grade | “1.8±0.4” | “1.7±0.4” | “1.8±0.4” | “1.8±0.4” |
| Fibrosis stage | “2.1±0.8” | “2.1±0.8” | “2.0±0.9” | “2.1±0.8” |
| Fibrosis stage F2 or F3, no. (%) | “63 (76)” | “68 (82)” | “57 (70)” | “188 (76)” |
| SAF-A score | “3.3±0.5” | “3.2±0.5” | “3.3±0.5” | “3.3±0.5” |
| NAS | “5.9±0.9” | “5.9±1.0” | “5.9±1.1” | “5.9±1.0” |
| NAS ≥6, no. (%) | “61 (73)” | “63 (76)” | “56 (69)” | “180 (73)” |
| Alanine aminotransferase, IU/liter | “63.6±43.4” | “64.1±41.4” | “56.9±31.6” | “61.6±39.2” |
| Aspartate aminotransferase, IU/liter | “43.9±24.8” | “53.9±43.4” | “43.3±24.1” | “47.1±32.3” |
| γ-Glutamyltransferase, IU/liter | “67.1±93.1” | “101.6±146.1” | “67.9±80.4” | “78.9±111.2” |
| Fasting HDL cholesterol, mmol/liter | “1.2±0.3” | “1.3±0.3” | “1.2±0.3” | “1.2±0.3” |
| Fasting triglycerides, mmol/liter | “2.0±0.9” | “1.9±0.9” | “2.0±0.8” | “2.0±0.9” |
| Fasting glucose, mmol/liter | “5.9±1.1” | “6.2±1.8” | “6.0±1.6” | “6.0±1.5” |
| Glycated hemoglobin, % | “6.1±0.7” | “6.1±0.8” | “6.0±0.7” | “6.0±0.7” |
| Fasting insulin, pmol/liter | “274.7±321.2” | “231.9±191.9” | “234.0±254.6” | “246.9±260.7” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.2-3"></a>

##### Baseline characteristics of participants with type 2 diabetes

> “A total of 103 patients who underwent randomization had type 2 diabetes mellitus; the mean age of these patients was 56 years, the mean body-mass index was 33, 62 (60%) were women, 83 (81%) had significant or advanced fibrosis, and 84 (82%) had an NAS of 6 or greater.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.2-4"></a>

##### Selection of more severe disease through the SAF-A criterion

> “The use of the SAF-A score leads to a selection of patients with more-severe disease activity and fibrosis,35 as was observed in the current trial, in which 76% of patients had significant or advanced fibrosis, despite the fact that no inclusion criterion with respect to fibrosis stage was set (except for the exclusion of patients with cirrhosis).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.2-5"></a>

##### Antidiabetic medication, prediabetes, obesity, and statin use in the enrolled population

> “Of 247 patients enrolled, 228 completed the study; mean age was 54 years, 58% were female, 94% were Caucasian, mean body mass index (BMI) was 33 kg/m2; 42% (n = 103) had T2D. Of these, 83% received metformin (alone or in combination anti-diabetic treatment), 22%, sulphonylurea; 11%, dipeptidyl peptidase-4 inhibitor; 7% sodium-glucose cotransporter-2 inhibitor medication; 13% had no antidiabetic treatment.”
> “Among 144 patients without T2D, 47 (33%) had prediabetes.”
> “Overall, 20% of patients took statins (22%, 22%, 16% with lanifibranor 1200 mg, 800 mg, and placebo respectively).”
> “Of 247 patients enrolled, 161 (65%) patients were obese (BMI ≥ 30) and 86 (35%) patients had a BMI < 30 at baseline (Supplementary Table 1).”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.2-6"></a>

##### Age categories and race in the registry results

| Characteristic | IVA337 1200mg | IVA337 800mg | Placebo | Total |
| --- | --- | --- | --- | --- |
| Age between 18 and 65 years | “67” | “69” | “63” | “199” |
| Age 65 years or older | “16” | “14” | “18” | “48” |
| American Indian or Alaska Native | “0” | “0” | “2” | “2” |
| Asian | “2” | “1” | “2” | “5” |
| Native Hawaiian or Other Pacific Islander | “0” | “1” | “0” | “1” |
| Black or African American | “3” | “1” | “3” | “7” |
| White | “78” | “80” | “74” | “232” |

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="topic-3.1.2.8.2-7"></a>

##### Region of enrollment in the registry results

| Country | IVA337 1200mg | IVA337 800mg | Placebo | Total |
| --- | --- | --- | --- | --- |
| Bulgaria | “17” | “16” | “22” | “55” |
| France | “15” | “15” | “9” | “39” |
| United States | “13” | “11” | “12” | “36” |
| Belgium | “10” | “11” | “11” | “32” |
| Australia | “3” | “7” | “3” | “13” |
| Germany | “7” | “3” | “3” | “13” |
| Spain | “3” | “4” | “5” | “12” |
| Czechia | “3” | “2” | “3” | “8” |
| Canada | “3” | “1” | “4” | “8” |
| United Kingdom | “3” | “2” | “2” | “7” |
| Mauritius | “2” | “3” | “2” | “7” |
| Poland | “1” | “2” | “3” | “6” |
| Italy | “3” | “1” | “1” | “5” |
| Switzerland | “0” | “3” | “1” | “4” |
| Austria | “0” | “1” | “0” | “1” |
| Slovenia | “0” | “1” | “0” | “1” |

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Primary endpoint: full analysis population with multiple imputation

> “In the full analysis population in which missing data were handled with multiple imputation, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis (the primary end point) was significantly higher among those who received the 1200-mg dose (55%), but not among those who received the 800-mg dose (48%), of lanifibranor than among those who received placebo (33%) (risk ratio for a response in the 1200-mg lanifibranor group vs. the placebo group, 1.7; 95% confidence interval [CI], 1.2 to 2.3; P=0.007; risk ratio in the 800-mg lanifibranor group vs. the placebo group, 1.5; 95% CI, 1.0 to 2.1; P=0.07) (Figure 1).”
> “In the analysis of the primary end point, an ascending Hochberg procedure was used to adjust for multiplicity testing (each dose of lanifibranor was compared with placebo).”
> “Missing data for the 34 patients in the full analysis population (11 in the 800-mg lanifibranor group, 9 in the 1200-mg lanifibranor group, and 14 in the placebo group had missing biopsy samples at week 24) were handled with multiple imputation (details are provided in the Supplementary Appendix).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-2"></a>

##### Primary endpoint: nonresponder imputation, complete-case, per-protocol, and F2 or F3 fibrosis analyses

> “Results were similar in the prespecified analyses in which missing data were imputed as nonresponses and in the complete-case analyses (Fig. S9 and Tables S4 and S5). The results were also similar in the per-protocol population and among 188 patients with significant or advanced fibrosis.”
> “Significant or advanced fibrosis (stages F2 and F3, respectively) was present in 188 patients (76%)”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-3"></a>

##### Key secondary histologic endpoints: multiple imputation

> “Analyses were performed with multiple imputation of missing data.”
> “Resolution of NASH without worsening of fibrosis at week 24 from baseline was observed in 49% of patients who received the 1200-mg dose of lanifibranor, in 39% of patients who received the 800-mg dose, and in 22% of patients who received placebo (risk ratio for a response in the 1200-mg lanifibranor group vs. the placebo group, 2.2; 95% CI, 1.5 to 3.3; and risk ratio in the 800-mg lanifibranor group vs. the placebo group, 1.7; 95% CI, 1.1 to 2.7) (Figure 1 and Table S5).”
> “Improvement in fibrosis stage of at least 1 without worsening of NASH was observed in 48% of patients in the 1200-mg lanifibranor group, in 34% of patients in the 800-mg lanifibranor group, and in 29% of patients in the placebo group (risk ratio in the 1200-mg lanifibranor group vs. the placebo group, 1.7; 95% CI, 1.2 to 2.5; and risk ratio in the 800-mg lanifibranor group vs. the placebo group, 1.2; 95% CI, 0.7 to 1.9) (Figure 1).”
> “Resolution of NASH and improvement in fibrosis stage of at least 1 (composite end point) was observed in 35% of patients in the 1200-mg lanifibranor group, in 25% of patients in the 800-mg lanifibranor group, and in 9% of patients in the placebo group (risk ratio in the 1200-mg lanifibranor group vs. the placebo group, 4.0; 95% CI, 2.0 to 7.7; and risk ratio in the 800-mg lanifibranor group vs. the placebo group, 2.6; 95% CI, 1.2 to 5.5) (Figure 1).”
> “In this trial, a dose-dependent improvement in SAF-A score and its individual components was noted with lanifibranor.”
> “In this trial, other findings from the secondary end-point analyses suggest that the 1200-mg dose of lanifibranor may have led to a regression of fibrosis.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-4"></a>

##### Histologic endpoints in participants with F2 or F3 fibrosis: journal report

> “Among patients with significant or advanced fibrosis, the results were also better in the lanifibranor groups than in the placebo group.”
> “When the analysis was restricted to patients with significant (stage F2) or advanced (stage F3) fibrosis (i.e., those who compose the target population for the treatment of noncirrhotic NASH according to regulatory guidance), similar results were obtained, a finding that supports the potential for benefits with lanifibranor as compared with placebo.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-5"></a>

##### Primary and key secondary histologic endpoints: ITT and per-protocol populations, company topline release

> “ITT: includes all patients randomized in the trial.”
> “PP: includes all patients with paired biopsies and without deviation impacting efficacy assessment.”
> “Statistically significant in accordance to the statistical analysis plan (SAP)”

Source: [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf)

| Endpoint at week 24 | ITT placebo | ITT lanifibranor 800 mg | ITT lanifibranor 1200 mg | PP placebo | PP lanifibranor 800 mg | PP lanifibranor 1200 mg |
| --- | --- | --- | --- | --- | --- | --- |
| Number of participants | “(N = 81)” | “(N = 83)” | “(N = 83)” | “(N = 62)” | “(N = 63)” | “(N = 69)” |
| Decrease of at least 2 points in SAF activity score (primary) | “27%” | “41% P=0.061” | “49% P=0.004*” | “34%” | “51% P=0.058” | “55% P=0.015*” |
| Resolution of NASH and no worsening of fibrosis | “19%” | “33% P=0.043*” | “45% P<0.001*” | “23%” | “40% P=0.039*” | “49% P=0.002*” |
| Improvement of fibrosis by at least one stage and no worsening of NASH | “24%” | “28% P=0.53” | “42% P=0.011*” | “29%” | “32% P=0.75” | “46% P=0.04*” |
| Resolution of NASH and improvement of fibrosis | “7%” | “21% P=0.017*” | “31% P<0.001*” | “10%” | “24% P=0.036*” | “33% P=0.001*” |
| Decrease of at least 2 points in NAS and no worsening of fibrosis | “32%” | “52% P=0.01*” | “64% P<0.001*” | “40%” | “62% P=0.02*” | “71% P<0.001*” |

Source: [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf)

<a id="topic-3.1.2.8.3-6"></a>

##### Resolution of NASH without worsening of fibrosis in participants with F2 or F3 fibrosis: ITT and per-protocol populations, company topline release

> “Resolution of NASH and no worsening of fibrosis(2) in F2/F3 patients(3)”
> “Includes 188 patients in the ITT population and 149 in the Per Protocol population.”

Source: [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf)

| Population | Placebo | Lanifibranor 800 mg | Lanifibranor 1200 mg |
| --- | --- | --- | --- |
| ITT, F2 or F3 fibrosis | “9%” | “34% P=0.011*” | “44% P<0.001*” |
| Per protocol, F2 or F3 fibrosis | “11%” | “40% P=0.016*” | “51% P<0.001*” |

Source: [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf)

<a id="topic-3.1.2.8.3-7"></a>

##### Histologic endpoints: participants with a response, missing data counted as nonresponse, registry results

> “Patients with missing data are considered as non-responders.”
> “Responders rates were compared between the placebo and lanifibranor 1200 mg at the end of the treatment period (week 24) using a Cochran Mantel Haenzel test stratified on diabetic status at baseline (that was the stratified factors in the randomisation).”

Source: [ClinicalTrials.gov NCT03008070 API record](https://clinicaltrials.gov/api/v2/studies/NCT03008070)

| Outcome measure at 24 weeks (participants with a response) | IVA337 1200mg | IVA337 800mg | Placebo |
| --- | --- | --- | --- |
| Overall number of participants analyzed | “83” | “83” | “81” |
| SAF-A decrease of at least 2 points with no worsening of CRN-F (primary) | “41” | “34” | “22” |
| NASH improvement (NAS decrease of at least 2 points without worsening of fibrosis) | “53” | “43” | “26” |
| NASH resolution and no worsening of fibrosis | “37” | “27” | “15” |
| Improvement of fibrosis by at least 1 stage and no worsening of NASH | “35” | “23” | “19” |
| Resolution of NASH and improvement of fibrosis by at least 1 stage | “26” | “17” | “6” |
| Activity (SAF-A) improvement | “62” | “54” | “40” |
| Steatosis (CRN-S) improvement | “54” | “46” | “21” |
| Lobular inflammation (CRN-I) improvement | “43” | “34” | “30” |
| Hepatocyte ballooning (CRN-B) improvement | “60” | “54” | “37” |
| Fibrosis (CRN-F) improvement | “36” | “28” | “22” |
| Modified Ishak fibrosis (ISHAK-F) improvement | “41” | “32” | “25” |

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="topic-3.1.2.8.3-8"></a>

##### Liver enzymes: adjusted mean change at week 24, completers in the full analysis population

> “Liver enzyme levels decreased and the levels of the majority of lipid, inflammatory, and fibrosis biomarkers improved in the lanifibranor groups.”
> “The adjusted mean decrease in alanine aminotransferase level was 25 U per liter in the 1200-mg lanifibranor group, 26 U per liter in the 800-mg lanifibranor group, and 1 U per liter in the placebo group (Table 2). The decreases in the aspartate aminotransferase and γ-glutamyltransferase levels were in a similar direction, with greater decreases in the lanifibranor groups than in the placebo group.”
> “Laboratory Measures at Week 24 among the Patients in the Full Analysis Population Who Completed the Trial.”
> “A total of 228 patients completed their week-24 visit.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

| Change from baseline (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
| --- | --- | --- | --- |
| Alanine aminotransferase, U/liter | “−24.54 (−32.06 to −17.01)” | “−26.08 (−33.67 to −18.50)” | “−1.40 (−9.04 to 6.25)” |
| Aspartate aminotransferase, U/liter | “−12.04 (−18.29 to −5.79)” | “−15.11 (−21.43 to −8.80)” | “−0.08 (−6.43 to 6.26)” |
| γ-Glutamyltransferase, U/liter | “−27.87 (−38.88 to −16.86)” | “−43.38 (−54.46 to −32.29)” | “4.41 (−6.76 to 15.58)” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-9"></a>

##### Lipids and apolipoproteins: adjusted mean change at week 24, completers in the full analysis population

> “Laboratory Measures at Week 24 among the Patients in the Full Analysis Population Who Completed the Trial.”
> “Also, the patients who received lanifibranor had an increase in HDL cholesterol level and a decrease in serum triglyceride level, two major cardiovascular risk factors.”
> “Adjusted mean absolute changes and 95% confidence intervals were derived with the use of mixed models for repeated measures”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

| Change from baseline (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
| --- | --- | --- | --- |
| Total cholesterol, mmol/liter | “−0.07 (−0.22 to 0.07)” | “−0.02 (−0.17 to 0.13)” | “0.01 (−0.14 to 0.16)” |
| Fasting HDL cholesterol, mmol/liter | “0.11 (0.06 to 0.15)” | “0.16 (0.12 to 0.21)” | “0.01 (−0.04 to 0.05)” |
| Fasting LDL cholesterol, mmol/liter | “0.03 (−0.11 to 0.16)” | “0.03 (−0.11 to 0.16)” | “0.01 (−0.12 to 0.15)” |
| Fasting triglycerides, mmol/liter | “−0.44 (−0.61 to −0.27)” | “−0.49 (−0.66 to −0.31)” | “0.06 (−0.12 to 0.23)” |
| Fasting apolipoprotein A1, mg/dl | “−4.39 (−8.64 to −0.13)” | “−0.29 (−4.61 to 4.04)” | “0.03 (−4.27 to 4.33)” |
| Fasting apolipoprotein B, mg/dl (exploratory) | “−11.61 (−15.64 to −7.57)” | “−11.51 (−15.61 to −7.41)” | “−1.85 (−5.79 to 2.09)” |
| Fasting apolipoprotein C3, μg/dl (exploratory) | “−9.98 (−17.74 to −2.22)” | “−8.08 (−16.02 to −0.13)” | “10.31 (2.67 to 17.94)” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-10"></a>

##### Glycemic markers and insulin resistance: adjusted mean change at week 24, completers in the full analysis population

> “The adjusted mean change in glycated hemoglobin level was −0.4% in the 1200-mg lanifibranor group, −0.4% in the 800-mg lanifibranor group, and 0.1% in the placebo group.”
> “Laboratory Measures at Week 24 among the Patients in the Full Analysis Population Who Completed the Trial.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

| Change from baseline (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
| --- | --- | --- | --- |
| Fasting glucose, mmol/liter | “−0.60 (−0.83 to −0.37)” | “−0.78 (−1.01 to −0.55)” | “0.24 (0.01 to 0.47)” |
| Glycated hemoglobin, % | “−0.41 (−0.51 to −0.32)” | “−0.38 (−0.47 to −0.28)” | “0.07 (−0.02 to 0.17)” |
| Fasting insulin, pmol/liter | “−114.91 (−138.09 to −91.73)” | “−118.66 (−141.66 to −95.67)” | “−35.7 (−58.59 to −12.82)” |
| Fasting HOMA-IR index score | “−5.46 (−6.60 to −4.32)” | “−5.79 (−6.92 to −4.65)” | “−1.47 (−2.59 to −0.35)” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-11"></a>

##### Glycemic markers in participants with type 2 diabetes: journal report

> “A total of 103 patients who underwent randomization had type 2 diabetes mellitus; the mean age of these patients was 56 years, the mean body-mass index was 33, 62 (60%) were women, 83 (81%) had significant or advanced fibrosis, and 84 (82%) had an NAS of 6 or greater.”
> “The patients with diabetes had improvements in histologic features of NASH that were similar to those in the full analysis population, and they had more pronounced reductions in fasting levels of glucose, insulin, and glycated hemoglobin than those observed in the full analysis population.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-12"></a>

##### Glycemic markers and adiponectin by diabetes status: mean absolute change at week 24, congress poster

> “Table 1. Metabolic Response By Diabetes Status (NATIVE, Week 24)”
> “Mean absolute change from baseline; adiponectin shown as fold-increase.”
> “N=247 (103 T2DM / 144 non-T2DM)”
> “Glucose, HbA1c and insulin resistance improve in patients with AND without T2DM.”

Source: [Holleboom et al. (2026)](https://inventivapharma.com/wp-content/uploads/Metabolic-Benefits-of-Lanifibranor-in-Patients-With-and-Without-Type-2-Diabetes_ParisMASH_poster.pdf)

| Parameter | T2DM, lanifibranor 800 mg | T2DM, lanifibranor 1200 mg | T2DM, placebo | No T2DM, lanifibranor 800 mg | No T2DM, lanifibranor 1200 mg | No T2DM, placebo |
| --- | --- | --- | --- | --- | --- | --- |
| Fasting plasma glucose, mmol/L | “−1.71” | “−0.88” | “+0.29” | “−0.49” | “−0.39” | “+0.16” |
| HbA1c, % | “−0.60” | “−0.72” | “+0.10” | “−0.21” | “−0.25” | “+0.08” |
| HOMA index | “−10.62” | “−5.52” | “−0.60” | “−3.42” | “−7.27” | “+0.11” |
| Adiponectin, fold increase | “4.12” | “4.44” | “1.11” | “3.62” | “4.54” | “1.00” |

Source: [Holleboom et al. (2026)](https://inventivapharma.com/wp-content/uploads/Metabolic-Benefits-of-Lanifibranor-in-Patients-With-and-Without-Type-2-Diabetes_ParisMASH_poster.pdf)

<a id="topic-3.1.2.8.3-13"></a>

##### Adiponectin and inflammatory markers: adjusted mean change at week 24, completers in the full analysis population

> “Laboratory Measures at Week 24 among the Patients in the Full Analysis Population Who Completed the Trial.”
> “There was a dose-dependent increase in serum adiponectin level, which suggests that there was an improvement in adipose-tissue function.”
> “Adjusted mean absolute changes and 95% confidence intervals were derived with the use of mixed models for repeated measures”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

| Change from baseline (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
| --- | --- | --- | --- |
| Adiponectin, μg/ml | “17.12 (14.29 to 19.96)” | “11.95 (8.97 to 14.94)” | “−0.35 (−3.20 to 2.50)” |
| High-sensitivity CRP, mg/liter | “−1.37 (−2.28 to −0.46)” | “−2.05 (−2.97 to −1.13)” | “0.11 (−0.81 to 1.03)” |
| Fibrinogen, g/liter | “−0.10 (−0.24 to 0.05)” | “−0.17 (−0.32 to −0.02)” | “0.02 (−0.12 to 0.17)” |
| α2-Macroglobulin, g/liter | “0.13 (0.04 to 0.22)” | “0.15 (0.06 to 0.24)” | “0.05 (−0.04 to 0.13)” |
| Haptoglobin, g/liter | “−0.07 (−0.13 to 0)” | “−0.05 (−0.12 to 0.01)” | “0.05 (−0.01 to 0.12)” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-14"></a>

##### Noninvasive tests of fibrosis, apoptosis, and steatosis: completers in the full analysis population

> “Mean transient elastography values decreased by 1.7 in the 1200-mg lanifibranor group, 1.0 in the 800-mg lanifibranor group, and 0.7 in the placebo group. The results with respect to controlled attenuation parameter were in a similar direction, with greater decreases in the lanifibranor groups than in the placebo group (Table S9).”
> “The histologic results are supported by apparent improvements in several relevant metabolic, inflammatory, and fibrogenesis markers, including Pro-C3 and liver stiffness, but other markers of fibrosis (scores on the Enhanced Liver Fibrosis test and Fibrosis-4 index) did not improve. However, as changes in biomarkers are not fully validated as surrogates of histologic change, these results should be interpreted with caution, particularly in short-term trials.”
> “Laboratory Measures at Week 24 among the Patients in the Full Analysis Population Who Completed the Trial.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

| Change from baseline in exploratory end points (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
| --- | --- | --- | --- |
| Pro-C3, μg/liter | “−1.79 (−3.07 to −0.52)” | “−3.93 (−5.26 to −2.61)” | “−1.01 (−2.30 to 0.28)” |
| TIMP-1 to MMP-2 ratio | “−0.75 (−0.93 to −0.57)” | “−0.69 (−0.88 to −0.50)” | “−0.11 (−0.29 to 0.08)” |
| Cytokeratin 18 M30, pmol/liter | “−315.55 (−441.55 to −189.55)” | “−331.71 (−463.78 to −199.65)” | “−105.03 (−232.86 to 22.80)” |
| Enhanced Liver Fibrosis test score | “0.11 (−0.04 to 0.26)” | “−0.19 (−0.35 to −0.04)” | “−0.08 (−0.23 to 0.06)” |
| Fibrosis-4 index score | “0.03 (−0.13 to 0.19)” | “0 (−0.17 to 0.16)” | “−0.03 (−0.19 to 0.13)” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-15"></a>

##### Cardiometabolic secondary and post hoc analyses: scope and multiplicity

> “This manuscript reports the results of several secondary objectives of the NATIVE trial, that were prespecified in the protocol and the Statistical Analysis Plan (SAP), including the effect of lanifibranor 1200 mg/day and 800 mg/day versus placebo on CMH markers, evaluated after 24 weeks of treatment (EOT) compared to baseline, and for some markers also at TW4.”
> “No multiplicity adjustments were performed for the analyses presented in this paper, that are considered exploratory.”
> “Limitations may include the fact that patients who meet study entry criteria may not represent all patients seen in varying practice environments; analyses were post-hoc of available data”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-16"></a>

##### Insulin resistance and glycemic control: adjusted mean difference versus placebo at end of treatment

> “Fasting insulin levels (FIL) significantly decreased with lanifibranor in the overall population; adjusted mean difference versus placebo [AMD] at end of treatment [EOT] was −79 pmol/L (95% confidence interval [CI]: −112 to −47, p < 0.001) with lanifibranor 1200 mg; −83 pmol/L (95%CI: −115 to −51, p < 0.001) with 800 mg.”
> “Overall, AMD was −0.8 mmol/L (95%CI: −1.2 to −0.5, p < 0.001) with 1200 mg and −1.0 mmol/L (95%CI: −1.4 to −0.7, p < 0.001) with 800 mg. With T2D, AMD in hemoglobin A1c (HbA1c) at EOT was −0.7% (95%CI: −1.0 to −0.4, p < 0.001) in both active arms. Overall, HbA1c was −0.5% (95%CI: −0.6 to −0.3, p < 0.001) with both lanifibranor 1200 mg and 800 mg (Table 1, Fig. 1F).”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-17"></a>

##### Glycemic status in participants with prediabetes or normoglycemia at baseline: post hoc analysis

> “With prediabetes, FG decreased at EOT to <5.6 mmol/L in 71% (95%CI: 48 to 95, p = 0.009) of patients on lanifibranor 1200 mg, 67% (95%CI: 45 to 88, p = 0.013) on 800 mg versus 11% (95%CI: 0 to 32) on placebo, indicating return to normoglycemia in the majority of lanifibranor-treated patients.”
> “Conversely, among 83 patients with normoglycemia at baseline, 0% with lanifibranor 1200 mg and 800 mg progressed to prediabetes at EOT, versus 26% (95%CI: 10 to 41, both p < 0.01) in the placebo arm (Supplementary Table 3).”
> “Further post-hoc analyses, i.e., not pre-specified in the SAP, included: the effects of therapy in the subgroups of patients with and without overt T2D; in patients with prediabetes at baseline”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-18"></a>

##### Lipids and apolipoproteins: adjusted mean difference versus placebo at end of treatment

> “Fasting total serum triglycerides (TG) levels decreased significantly with lanifibranor compared to placebo, with an AMD at EOT of −0.5 mmol/L (95%CI: −0.8 to −0.3, equivalent to −44.3 mg/dL, p < 0.001) with both lanifibranor 1200 mg and 800 mg groups (Table 1).”
> “Among the 109 patients with high baseline TG values (>1.7 mmol/L, 150.5 mg/dL), 60% and 70% on lanifibranor 1200 mg and 800 mg, respectively, improved to low-risk TG levels of ≤1.7 mmol/L at EOT, versus 27% on placebo (Supplementary Fig. 1).”
> “No significant LDL-C change was observed with either lanifibranor dose versus placebo (Table 1, Fig. 1C).”
> “Lanifibranor significantly reduced APO-B with an AMD at EOT of −10 mg/dL (95%CI: −15 to −4, p < 0.001) with both doses (Table 1, Fig. 1D)”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-19"></a>

##### Systemic inflammation and ferritin: adjusted mean difference versus placebo at end of treatment

> “With lanifibranor 1200 mg and 800 mg respectively, AMD at EOT was −1.5 mg/L (95%CI: −2.8 to −0.2, p = 0.026) and −2.2 mg/L (95%CI: −3.5 to −0.9, p = 0.001)”
> “At EOT, levels decreased significantly with lanifibranor (AMD at EOT: −84.2 µg/L [95%CI: −125.2 to –43.3], −71.8 µg/L [95%CI: −112.6 to −31.0] for lanifibranor 800 mg and 1200 mg, respectively, both p < 0.001), but were unchanged with placebo (Table 1, Fig. 1H).”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-20"></a>

##### Blood pressure: adjusted mean difference versus placebo at end of treatment

> “From TW4 and maintained during treatment, diastolic BP (DBP) decreased with both lanifibranor doses (AMD at EOT was −2.5 mmHg [95%CI: −5.5 to 0.6, p = 0.110] with lanifibranor 1200 mg and −3.9 mmHg [95%CI: −6.9 to −0.9, p = 0.012] with 800 mg, [Table 1, Fig. 1I]). Systolic BP did not change significantly.”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-21"></a>

##### Hepatic steatosis by histology and controlled attenuation parameter

> “Histological steatosis improved significantly at EOT with lanifibranor versus placebo, with more than 35% of patients improving by at least 2 grades with lanifibranor versus 5% with placebo (Fig. 2A).”
> “Controlled attenuation parameter (CAP™) similarly decreased significantly at EOT with lanifibranor (AMD at EOT was −23 dB/m [95%CI: −41 to −5, p = 0.012] with 1200 mg and −16 dB/m [95%CI: −33 to 1, p = 0.070] with 800 mg [Table 1]) but not with placebo (Fig. 2C).”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-22"></a>

##### Cardiometabolic and hepatic markers by weight change group: post hoc analysis

> “In pooled lanifibranor arms, all CMH markers, i.e., steatosis, HOMA-IR, FIL, lipids (HDL-C, TG, APO-B, APO-C3, APO-B/APO-A), FG, hs-CRP, ferritin and DBP, as well as liver tests (ALT, AST, gamma-glutamyl transferase [GGT]), improved to the same degree in the three weight-change groups. In contrast, placebo-treated patients with increased weight at EOT had unchanged or worsening values of these markers.”
> “Further post-hoc analyses, i.e., not pre-specified in the SAP, included”
> “the correlation between weight changes (both continuous and by weight-change group, i.e., <2.5%, 2.5−5% and ≥5% increase from baseline) under lanifibranor and placebo, separately, and improvement in CMH markers”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-23"></a>

##### Adiponectin response and histologic improvement

> “Higher increase of adiponectin levels was observed in the lanifibranor 1200 mg (mean fold 4.5) compared to lanifibranor 800 mg (3.8) at EOT, 86% of patients on lanifibranor 800 mg had moderate (58%) or high (29%) increase and 95% of those on 1200 mg had moderate (52%) or high (42%) increase. With placebo only 10% had moderate, and none high increase (Supplementary Table 6).”
> “Absolute and categorical (fold change) adiponectin increase also correlated with improvement of liver histological endpoints for disease activity, i.e., CRN-NAFLD activity score (NAS) and individual activity components (ballooning and inflammation), and with improvement in fibrosis stage (38% versus 57% for adiponectin increase ≤4- versus >4-fold, respectively) (Supplementary Table 8, Fig. 5A−D).”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-24"></a>

##### Cardiometabolic markers in obese and non-obese participants

> “Of 247 patients enrolled, 161 (65%) patients were obese (BMI ≥ 30) and 86 (35%) patients had a BMI < 30 at baseline (Supplementary Table 1). Overall, the effects of lanifibranor therapy versus placebo on markers of CMH and on liver tests were similar for obese and non-obese patients (Supplementary Table 13).”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-25"></a>

##### Adiponectin fold change at end of treatment by arm and relation to weight change: congress poster

> “Circulating ADP levels were measured at baseline (BL) and end of treatment (EOT) in 211 patients; weight-based CMH analyses were performed in 217 completers.”
> “With lanifibranor, 87% of patients had an ADP increase at EOT vs only 10% of placebo patients; among placebo patients, all increases were < 4-fold.”
> “Lanifibranor induced robust adiponectin increases that were associated with improvements in MASH histology and cardiometabolic health. These effects were independent of body-weight change.”

Source: [Rinella et al. (2026b)](https://inventivapharma.com/wp-content/uploads/ADP-and-Weight-Gain-Correlation-Poster_EASL2624.pdf)

| Fold adiponectin at week 24 | Placebo | Lanifibranor 800 mg | Lanifibranor 1200 mg | Lanifibranor pooled |
| --- | --- | --- | --- | --- |
| Number of participants | “72” | “66” | “73” | “139” |
| Mean (SD) | “1.1 ± 0.3” | “3.8 ± 3.1” | “4.5 ± 3.5” | “4.2 ± 3.3” |
| Unchanged | “65 (90%)” | “9 (14%)” | “4 (5%)” | “13 (9%)” |
| Fold 1.5 to 4 | “7 (10%)” | “38 (58%)” | “38 (52%)” | “76 (55%)” |
| Fold more than 4 | “0 (0.0%)” | “19 (29%)” | “31 (42%)” | “50 (36%)” |

Source: [Rinella et al. (2026b)](https://inventivapharma.com/wp-content/uploads/ADP-and-Weight-Gain-Correlation-Poster_EASL2624.pdf)

<a id="topic-3.1.2.8.3-26"></a>

##### Serum biomarker signatures of histologic response: pooled lanifibranor arms

> “Patients receiving lanifibranor were pooled, and those with liver biopsies were selected (n = 142). A panel of 65 biomarkers were evaluated by assessing baseline and absolute as well as relative changes at the end of treatment.”
> “The biomarkers included in E1 score (baseline adiponectin and ferritin; delta of matrix metalloproteinase 9 and transferrin), E2 score (baseline cytokeratin 18 Fragment M65; delta of hyaluronic acid, fructosamine, and alanine aminotransferase), and E3 score (baseline cytokeratin 18 Fragment M65 and gamma-glutamyl transferase; delta of aspartate aminotransferase, insulin, and urea) represented metabolic, apoptotic, and fibrosis aspects of the disease. These signatures provided good accuracy for the noninvasive identification of histologic response under lanifibranor with area under the receiver operating characteristic curve at 0.81 ± 0.08 for E1 score, 0.80 ± 0.08 for E2 score, and 0.81 ± 0.08 for E3 score.”
> “Results from this analysis show evidence that baseline values and changes in selected serum biomarkers can aid in predicting histologic response in MASH under lanifibranor treatment.”

Source: [Boursier et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40107637/)

<a id="topic-3.1.2.8.3-27"></a>

##### Liver sinusoidal endothelial cell capillarisation (CD34 staining) at baseline and week 24

> “Among the latter, 173 patients had baseline liver tissue available for CD34 staining, including 163 with liver tissue also available at week 24.”
> “In patients with MASH randomised into the NATIVE trial, 24-week treatment with lanifibranor at both dosages had no effect on the density of CD34-positive vessels (Fig. 5A). Improvement in periportal score was more common in patients treated with lanifibranor than in those treated with placebo, with a dose–response effect (placebo: 7.5%. lanifibranor 800 mg: 18.5%. lanifibranor 1,200 mg: 23.2%. p = 0.025, Fig. 5C). Patients with lanifibranor treatment had less worsening of lobular score (placebo: 39.6%, lanifibranor 800 mg: 18.5%, lanifibranor 1,200 mg: 23.2%; p = 0.028, Fig. 5F).”

Source: [Rautou et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12142333/)

<a id="topic-3.1.2.8.3-28"></a>

##### Histologic and metabolic response by PNPLA3 genotype: congress poster

> “Of these, 219 patients consented to genotyping for the PNPLA3 rs738409 SNP. Sixty five were II, 105 IM and 49 MM, which is highest risk for disease severity and progression.”
> “There was no significant difference in response to lanifibranor by PNPLA3 genotype, despite the fact that MM genotype patients had more activity on biopsy than the II or IM patients (82% NAS≥6, vs 74%, 70%), while there was no difference in fibrosis.”
> “The efficacy of lanifibranor on both liver histology and markers of cardiometabolic health appears to be independent of PNPLA3 status, despite MM genotype patients having more severe activity on liver biopsy.”

Source: [Griffel et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD23-PNPLA3_V1.0_20231013.pdf)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

##### SF-36 and Flinders Fatigue Scale at week 24

> “With regard to quality of life, no substantial changes from baseline in the various dimensions of the Medical Outcomes Study 36-Item Short-Form Health Survey and the score on the Flinders Fatigue Scale were observed at week 24 (Table S10).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Adverse event overview: full analysis population, treatment period

> “Overview of Adverse Events That Occurred during the Treatment Period (Full Analysis Population).”
> “The treatment period was defined as the period after the first dose up to 28 days after the last dose.”
> “Most adverse events were mild or moderate in severity (Table 3).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

| Event, number (percent) | Lanifibranor 1200 mg (N=83) | Lanifibranor 800 mg (N=83) | Placebo (N=81) |
| --- | --- | --- | --- |
| At least 1 adverse event | “62 (75)” | “59 (71)” | “50 (62)” |
| Mild | “54 (65)” | “51 (61)” | “42 (52)” |
| Moderate | “28 (34)” | “20 (24)” | “22 (27)” |
| Severe | “3 (4)” | “3 (4)” | “3 (4)” |
| Adverse event related to active drug or placebo, as assessed by the investigator | “23 (28)” | “25 (30)” | “19 (23)” |
| Adverse event that led to permanent discontinuation of the trial regimen | “3 (4)” | “4 (5)” | “3 (4)” |
| Adverse event related to active drug or placebo that led to discontinuation | “2 (2)” | “1 (1)” | “2 (2)” |
| Serious adverse event | “7 (8)” | “3 (4)” | “3 (4)” |
| Death | “0” | “0” | “0” |
| Serious adverse event related to active drug or placebo | “0” | “0” | “2 (2)” |
| Serious postprocedural condition linked to biopsy procedure | “3 (4)” | “1 (1)” | “0” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.5-2"></a>

##### Most frequent adverse events by arm: full analysis population

> “Overview of Adverse Events That Occurred during the Treatment Period (Full Analysis Population).”
> “Adverse events are listed for those that occurred in more than 5% of patients in either lanifibranor group.”
> “Nausea, diarrhea, peripheral edema, anemia, and weight gain occurred more frequently with lanifibranor than with placebo.”
> “Fatigue included asthenia.”
> “Anemia included iron deficiency anemia and decreased hemoglobin level.”
> “Increase in aminotransferase level included increased alanine aminotransferase level, increased aspartate aminotransferase level, or abnormal liver function test result.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

| Adverse event, number (percent) | Lanifibranor 1200 mg (N=83) | Lanifibranor 800 mg (N=83) | Placebo (N=81) |
| --- | --- | --- | --- |
| Diarrhea | “10 (12)” | “8 (10)” | “1 (1)” |
| Fatigue | “11 (13)” | “3 (4)” | “8 (10)” |
| Nausea | “7 (8)” | “8 (10)” | “3 (4)” |
| Weight gain | “7 (8)” | “8 (10)” | “0” |
| Peripheral edema | “7 (8)” | “5 (6)” | “2 (2)” |
| Headache | “7 (8)” | “4 (5)” | “4 (5)” |
| Abdominal pain | “5 (6)” | “4 (5)” | “4 (5)” |
| Dizziness | “6 (7)” | “2 (2)” | “3 (4)” |
| Anemia | “6 (7)” | “1 (1)” | “0” |
| Constipation | “5 (6)” | “3 (4)” | “6 (7)” |
| Increase in aminotransferase level | “3 (4)” | “5 (6)” | “1 (1)” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.5-3"></a>

##### Serious adverse events by arm: full analysis population

> “Overview of Adverse Events That Occurred during the Treatment Period (Full Analysis Population).”
> “There were two serious adverse events (mild heart failure and urticaria, both in the placebo group) that were determined by the investigator to be related to the placebo.”
> “There were two suspected unexpected serious adverse reactions; one patient had mild cardiac failure, and one patient had moderate urticaria.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

| Other serious adverse event, number (percent) | Lanifibranor 1200 mg (N=83) | Lanifibranor 800 mg (N=83) | Placebo (N=81) |
| --- | --- | --- | --- |
| Wrist fracture | “0” | “0” | “1 (1)” |
| Unstable angina | “1 (1)” | “0” | “0” |
| Heart failure | “0” | “0” | “1 (1)” |
| Gastroenteritis | “1 (1)” | “0” | “0” |
| Pyelonephritis | “1 (1)” | “0” | “0” |
| Pancreatitis | “0” | “1 (1)” | “0” |
| Undifferentiated connective tissue disease | “0” | “1 (1)” | “0” |
| Urticaria | “0” | “0” | “1 (1)” |
| Foot operation | “1 (1)” | “0” | “0” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.5-4"></a>

##### Discontinuations and severe adverse events

> “The assigned regimen was discontinued because of adverse events in three patients (4%) in the 1200-mg lanifibranor group, in four patients (5%) in the 800-mg lanifibranor group, and in three patients (4%) in the placebo group.”
> “In each trial group, three patients (4%) had a severe adverse event during the treatment period (defined as the period after the first dose up to 28 days after the last dose).”
> “One patient had mild cardiac failure, and one patient had mild diarrhea, abdominal pain, and dizziness.”
> “One patient had moderate diarrhea.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.5-5"></a>

##### Peripheral edema: journal report

> “Peripheral edema that was assessed by the investigator as being related to the active drug or placebo occurred in four patients (2%) in the lanifibranor groups (two in each group) and in no patient in the placebo group during the treatment period. One patient had severe peripheral edema but recovered after discontinuing the 1200-mg regimen of lanifibranor for 12 days; treatment was resumed without reoccurrence of edema.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.5-6"></a>

##### Peripheral edema: character, management, and sex of participants with drug-related cases, company presentation

> “Peripheral edema (bilateral ankle edema): usually mild, in most cases no treatment was required, a few patients received diuretics.”
> “4 cases were considered study drug related by the investigator (2 at 800 and 1200 mg each). One case of severe intensity, which resolved by stopping treatment (lanifibranor 1200mg) for 12 days, without reoccurrence when the study treatment was resumed. All were female patients.”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.2.8.5-7"></a>

##### Body weight: mean change from baseline at week 24

> “A mean increase of 2.7 kg (3.1%) from baseline in body weight was observed among the patients in the 1200-mg lanifibranor group, and a mean increase of 2.4 kg (2.6%) was observed among the patients in the 800-mg lanifibranor group (Fig. S7).”
> “This improvement in adipose tissue function is most likely the main reason for the observed increase in body weight.”
> “Lanifibranor induced a histologic improvement despite this weight gain, which could be explained by the role of adipose-tissue dysfunction rather than overweight per se in the pathophysiology of NASH”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.5-8"></a>

##### Body weight: distribution of weight change at end of treatment, pooled lanifibranor arms

> “patients had an average weight gain of 2.5 kg, with 49% gaining ≥2.5% weight”
> “Weight change showed considerable interindividual variability: at EOT, 51% of patients in pooled lanifibranor arms had stable weight (≤2.5% increase), 16% had moderate increase (2.5−5%), and 33% had ≥5% increase from baseline; with placebo 84% had stable weight, but 16% had >2.5% weight increase (Supplementary Fig. 3).”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.5-9"></a>

##### Body weight: weight change category at week 24 by arm, completers, congress poster

> “weight-based CMH analyses were performed in 217 completers”
> “only two weight change groups for placebo due to few patients >5%.”

Source: [Rinella et al. (2026b)](https://inventivapharma.com/wp-content/uploads/ADP-and-Weight-Gain-Correlation-Poster_EASL2624.pdf)

| Weight at week 24 | Placebo | Lanifibranor 800 mg | Lanifibranor 1200 mg | Lanifibranor pooled |
| --- | --- | --- | --- | --- |
| Number of participants | “73” | “71” | “73” | “144” |
| Stable (2.5% or less) | “61 (84%)” | “41 (58%)” | “32 (44%)” | “73 (51%)” |
| Increase (more than 2.5%), placebo only | “12 (16%)” | “–” | “–” | “–” |
| Increase (2.5% to 5%) | “–” | “9 (13%)” | “14 (19%)” | “23 (16%)” |
| Increase (more than 5%) | “–” | “21 (30%)” | “27 (37%)” | “48 (33%)” |

Source: [Rinella et al. (2026b)](https://inventivapharma.com/wp-content/uploads/ADP-and-Weight-Gain-Correlation-Poster_EASL2624.pdf)

<a id="topic-3.1.2.8.5-10"></a>

##### Anemia and hemoglobin

> “Anemia was reported in six patients (7%) in the 1200-mg lanifibranor group, with the hemoglobin levels returning to pretreatment values after either investigator-initiated iron supplementation or discontinuation of lanifibranor. A relative reduction in hemoglobin levels of 5 to 6% from baseline was observed in the lanifibranor groups, as compared with a 1% reduction in the placebo group (Fig. S8).”
> “A reduction in hemoglobin levels was observed in the lanifibranor groups, a finding that is consistent with those in previous reports of other compounds with PPARγ agonism; such a reduction has several potential underlying mechanisms.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.5-11"></a>

##### Heart failure and NT-proBNP

> “One patient in the 1200-mg lanifibranor group was reported by the investigator to have nontreatment-related mild heart failure that did not lead to further investigation or hospitalization.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

> “N-terminal pro b-type natriuretic peptide (NT-proBNP) increased with both lanifibranor doses; AMD at EOT was 8.4 pmol/L (71 pg/mL) with lanifibranor 1200 mg and 4.0 pmol/L (34 pg/mL) with 800 mg (Table 1, Fig. 1J), this increase being correlated with weight increase (Supplementary Table 4, Fig. 3G).”
> “While PPARγ-associated weight gain is thus indicative of maturation of adipose tissue, some contributing effect on fluid retention is suggested by the treatment effect on NT-proBNP.”
> “There was no clinical evidence for congestion in patients on lanifibranor in NATIVE.”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.5-12"></a>

##### Kidney function and bone turnover

> “Kidney function (markers included creatinine and urea levels and estimated glomerular filtration rate) (Table S11) and bone turnover (markers included osteocalcin level and beta-CrossLaps value [the level of β-isomer of the C-terminal telopeptide of type I collagen, as measured with a CrossLaps osteometer, Biotech]) (Table S12) were not impaired.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.5-13"></a>

##### Serious adverse events: registry results

> “On or after the first dose of treatment up to 30 days post last dose.”
> “Term from vocabulary, MedDRA 20.0”

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

| Serious adverse event, affected / at risk (%) | IVA337 1200mg | IVA337 800mg | Placebo |
| --- | --- | --- | --- |
| All-cause mortality | “0/83 (0.00%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Total serious adverse events | “7/83 (8.43%)” | “3/83 (3.61%)” | “3/81 (3.70%)” |
| Angina unstable | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Cardiac failure | “0/83 (0.00%)” | “0/83 (0.00%)” | “1/81 (1.23%)” |
| Pancreatitis | “0/83 (0.00%)” | “1/83 (1.20%)” | “0/81 (0.00%)” |
| Pneumobilia | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Gastroenteritis | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Pyelonephritis | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Post procedural haematoma | “2/83 (2.41%)” | “1/83 (1.20%)” | “1/81 (1.23%)” |
| Post procedural haemorrhage | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Procedural pain | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Wrist fracture | “0/83 (0.00%)” | “0/83 (0.00%)” | “1/81 (1.23%)” |
| Undifferentiated connective tissue disease | “0/83 (0.00%)” | “1/83 (1.20%)” | “0/81 (0.00%)” |
| Urticaria | “0/83 (0.00%)” | “0/83 (0.00%)” | “1/81 (1.23%)” |
| Foot operation | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="topic-3.1.2.8.5-14"></a>

##### Other adverse events at the 5% reporting threshold: registry results

> “Frequency Threshold for Reporting Other Adverse Events”
> “Indicates events were collected by non-systematic assessment”

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

| Other adverse event, affected / at risk (%) | IVA337 1200mg | IVA337 800mg | Placebo |
| --- | --- | --- | --- |
| Total | “60/83 (72.29%)” | “48/83 (57.83%)” | “30/81 (37.04%)” |
| Diarrhoea | “10/83 (12.05%)” | “8/83 (9.64%)” | “1/81 (1.23%)” |
| Nausea | “7/83 (8.43%)” | “8/83 (9.64%)” | “3/81 (3.70%)” |
| Constipation | “5/83 (6.02%)” | “3/83 (3.61%)” | “6/81 (7.41%)” |
| Fatigue | “11/83 (13.25%)” | “3/83 (3.61%)” | “8/81 (9.88%)” |
| Oedema peripheral | “7/83 (8.43%)” | “5/83 (6.02%)” | “2/81 (2.47%)” |
| Viral upper respiratory tract infection | “3/83 (3.61%)” | “3/83 (3.61%)” | “5/81 (6.17%)” |
| Weight increased | “7/83 (8.43%)” | “8/83 (9.64%)” | “0/81 (0.00%)” |
| Transaminases increased | “3/83 (3.61%)” | “5/83 (6.02%)” | “1/81 (1.23%)” |
| Headache | “7/83 (8.43%)” | “4/83 (4.82%)” | “4/81 (4.94%)” |
| Dizziness | “6/83 (7.23%)” | “2/83 (2.41%)” | “3/81 (3.70%)” |

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary: duration, sample size, histology reading, and sponsor role

- Treatment lasted 24 weeks; the protocol states that 6 months is sufficient in a proof-of-concept study and limits the time on placebo.
- The protocol planned 225 randomized participants (75 per arm) for at least 80% power with a two-sided alpha of 0.025, assuming a placebo responder rate of 10% and an excess responder rate of 20%. The placebo response on the primary endpoint was 33% in the multiple imputation analysis of the journal report and 27% in the intention-to-treat population of the company topline release. A total of 247 participants were randomized (83, 83, and 81) out of 868 screened.
- All biopsy samples were read by one pathologist who was unaware of timing and group assignment.
- No fibrosis-stage inclusion criterion was set other than exclusion of cirrhosis; 188 participants (76%) had stage F2 or F3 fibrosis, and results in this group come from a subgroup analysis.
- The journal report states that the validity of the SAF-A score as a surrogate for long-term outcomes “warrants further study”, and that changes in noninvasive biomarkers should be interpreted with caution, “particularly in short-term trials”.
- The sponsor designed the trial, monitored the sites, collected the data, and analyzed the data.

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf); [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205); [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf); [Francque et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33038502/)

<a id="topic-3.1.2.9-2"></a>

#### Summary: missing biopsies, analysis methods, protocol changes, and figures that differ by source

- Week 24 biopsies were missing for 34 participants (11 at 800 mg, 9 at 1200 mg, and 14 with placebo). The protocol specified that an amendment would be submitted to increase the sample size if end-of-study slides were unavailable or uninterpretable in more than 5% of participants.
- The protocol's primary rule counted missing data as nonresponse; the journal report's primary analysis used multiple imputation. With multiple imputation, the primary endpoint was met by 55% with 1200 mg and 48% with 800 mg versus 33% with placebo (P=0.007 and P=0.07). The company topline release (intention-to-treat, all randomized) gives 49% (P=0.004) and 41% (P=0.061) versus 27%, and the registry, counting missing data as nonresponse, gives 41 of 83, 34 of 83, and 22 of 81 responders. The journal report states that nonresponder imputation and complete-case results were similar.
- No multiplicity adjustments were defined for secondary and exploratory end points. The cardiometabolic analyses of Cooreman et al. had no multiplicity adjustment, are considered exploratory, and include post hoc analyses.
- Protocol version 5.0, dated July 9, 2019, updated the secondary endpoints. The registry states that the last participant was recruited in March 2019, and the journal report gives a screening period of February 2017 through July 2019.
- The selection period is 3 days to 4 weeks in the protocol and 10 days to 4 weeks in the registry.
- Discontinuations for adverse events are 3 (4%), 4 (5%), and 3 (4%) in the journal report (1200 mg, 800 mg, placebo) and 3, 3, and 3 in the registry participant flow, which lists one further 800 mg participant under “Withdrawal by patient and adverse event non fatal”.

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205); [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf); [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf); [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results); [ClinicalTrials.gov NCT03008070 API record](https://clinicaltrials.gov/api/v2/studies/NCT03008070); [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070); [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.9-3"></a>

#### Summary: enrolled population and generalizability

- Of 247 participants, 232 (94%) were White and 103 (42%) had type 2 diabetes. By registry region of enrollment, 55 were enrolled in Bulgaria, 39 in France, and 36 in the United States.
- The protocol required GLP-1 receptor agonists, vitamin E, fibrates, and PPAR gamma agonists to be stopped before randomization, and the registry excluded participants with type 2 diabetes on insulin, HbA1c >8.5%, or body mass index >45 kg/m2.
- Cooreman et al. state that participants who meet study entry criteria may not represent all patients seen in varying practice environments.

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205); [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results); [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf); [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070); [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
